Featured Research

from universities, journals, and other organizations

Novel treatment for drug-resistant tuberculosis shows promise, but concerns for patient safety remain

Date:
July 11, 2014
Source:
The Lancet
Summary:
Community health experts call for balanced approach to continued development of promising new TB drug in a new article. They argue that research into bedaquiline -- a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) -- should proceed cautiously in people with drug-sensitive tuberculosis.

In a viewpoint published this week in The Lancet, the Community Research Advisors Group (CRAG) argue that research into bedaquiline -- a new drug, fast tracked for multidrug-resistant tuberculosis (MDR-TB) -- should proceed cautiously in people with drug-sensitive tuberculosis. CRAG, an international, community-based advisory board for the US Centers for Disease Control and Prevention's Tuberculosis Trials Consortium, writing in The Lancet independently, urge researchers to balance the goal of shortening treatment for drug-sensitive TB with patient safety.

Related Articles


Bedaquiline is the first novel drug to be approved for treatment of tuberculosis in forty years. The FDA fast-tracked the approval of the drug after phase 2 studies showed bedaquiline's promising activity against MDR-TB (the drug reduced the average time to a negative TB culture from 18 to 12 weeks, and increased the proportion of participants with a negative culture at 6 months from 58% to 79%). Current treatments for drug-resistant tuberculosis show improved outcomes when continued for 18 to 24 months, and even then cure rates range from 11% to 79% depending on the extent of resistance. This presents a huge burden both on health care facilities and on patients to stick to a strict, toxic, and lengthy regimen, often in settings where available resources and cost make long drug treatments difficult to implement.

However, along with the potential benefits of bedaquiline, the authors point out that the drug presents several safety concerns that should be addressed before testing the drug in people with drug-sensitive TB, who already have a very effective treatment option and as such face different risk-benefit considerations than people with drug-resistant TB. In one phase 2 trial, a significantly higher number of participants receiving bedaquiline died than those receiving placebo. The majority of these deaths had no common cause and occurred months after the trial ended, but due to the long half-life of the drug, adverse effects from the drug cannot be ruled out. Close follow-up monitoring is needed due to an increased rate of liver and cardiac toxicity observed in patients receiving bedaquiline, say the authors.

The authors also call on the drug's developer, Janssen, to make information regarding the drug's safety available to public research groups, and to immediately begin trials on the effects of the drug in populations that use alcohol and drugs, and that have Hepatitis B and C. These groups could both benefit greatly from future shortened tuberculosis treatment regimens, but are also at a greater risk of some of the drug's reported side effects.

According to CRAG co-chair Dorothy Namutamba, "Although up to this point it has only been studied as an addition to existing regimens for drug-resistant tuberculosis, bedaquiline shows a lot of promise for improving treatment in the future. However, the drug also shows potentially serious adverse effects ranging from liver toxicity, disruption of the heart's electrical rhythm, and even death. As trials of this novel drug are considered in patients with drug-sensitive tuberculosis, researchers need to carefully balance the potential benefit of the new drug while making sure to always place the safety of the trial participants at the forefront of any considerations."


Story Source:

The above story is based on materials provided by The Lancet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Laia Ruiz Mingote, Dorothy Namutamba, Francis Apina, Nomampondo Barnabas, Carmen Contreras, Taharqa Elnour, Mike Watson Frick, Cynthia Lee, Barbara Seaworth, Debra Shelly, Natalie Skipper, Ezio Tavora dos Santos Filho. The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities. The Lancet, 2014; DOI: 10.1016/S0140-6736(14)60523-7

Cite This Page:

The Lancet. "Novel treatment for drug-resistant tuberculosis shows promise, but concerns for patient safety remain." ScienceDaily. ScienceDaily, 11 July 2014. <www.sciencedaily.com/releases/2014/07/140711092043.htm>.
The Lancet. (2014, July 11). Novel treatment for drug-resistant tuberculosis shows promise, but concerns for patient safety remain. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2014/07/140711092043.htm
The Lancet. "Novel treatment for drug-resistant tuberculosis shows promise, but concerns for patient safety remain." ScienceDaily. www.sciencedaily.com/releases/2014/07/140711092043.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Reuters - Innovations Video Online (Oct. 29, 2014) A Swedish amputee who became the first person to ever receive a brain controlled prosthetic arm is able to manipulate and handle delicate objects with an unprecedented level of dexterity. The device is connected directly to his bone, nerves and muscles, giving him the ability to control it with his thoughts. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Google To Use Nanoparticles, Wearables To Detect Disease

Google To Use Nanoparticles, Wearables To Detect Disease

Newsy (Oct. 29, 2014) Google X wants to improve modern medicine with nanoparticles and a wearable device. It's all an attempt to tackle disease detection and prevention. Video provided by Newsy
Powered by NewsLook.com
Can Drinking Milk Lead To Early Death?

Can Drinking Milk Lead To Early Death?

Newsy (Oct. 29, 2014) Researchers in Sweden released a study showing heavy milk drinkers face an increased mortality risk from a variety of causes. Video provided by Newsy
Powered by NewsLook.com
Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins